85,267 Shares in Guardant Health, Inc. (NASDAQ:GH) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 85,267 shares of the company's stock, valued at approximately $2,605,000. Susquehanna Fundamental Investments LLC owned 0.07% of Guardant Health as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Nebula Research & Development LLC increased its stake in Guardant Health by 35.2% during the 4th quarter. Nebula Research & Development LLC now owns 51,845 shares of the company's stock worth $1,584,000 after buying an additional 13,484 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Guardant Health by 392.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 279,800 shares of the company's stock valued at $8,548,000 after acquiring an additional 223,000 shares in the last quarter. Hood River Capital Management LLC raised its position in Guardant Health by 5.8% in the 4th quarter. Hood River Capital Management LLC now owns 200,957 shares of the company's stock valued at $6,139,000 after purchasing an additional 11,079 shares in the last quarter. Dark Forest Capital Management LP purchased a new position in shares of Guardant Health in the 4th quarter valued at about $321,000. Finally, Harvest Investment Services LLC acquired a new position in shares of Guardant Health during the fourth quarter worth about $209,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on GH. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. UBS Group upped their price objective on Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday. Mizuho initiated coverage on Guardant Health in a research report on Thursday, April 10th. They set an "outperform" rating and a $55.00 target price on the stock. The Goldman Sachs Group upped their price target on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, Stephens reissued an "overweight" rating and set a $55.00 price objective on shares of Guardant Health in a report on Wednesday, March 26th. Twenty-one equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Guardant Health has an average rating of "Buy" and a consensus price target of $51.86.

Guardant Health Price Performance

Shares of GH stock traded down $1.95 during mid-day trading on Monday, hitting $44.90. The stock had a trading volume of 1,255,198 shares, compared to its average volume of 2,189,256. The firm has a market cap of $5.56 billion, a PE ratio of -12.61 and a beta of 1.49. The company's 50-day simple moving average is $43.74 and its 200-day simple moving average is $38.36. Guardant Health, Inc. has a fifty-two week low of $18.01 and a fifty-two week high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. During the same quarter last year, the firm earned ($0.46) earnings per share. The firm's revenue was up 20.8% compared to the same quarter last year. On average, analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.